日本語 >>
TOP page
Publications
Journal Articles
Presentations
（Last updated : 2024-07-29 14:10:21）
Takeshi Nagasaka
Department
Kawasaki Medical School Kawasaki Medical School, Department of Advanced Oncology,
Position
Professor
■
Publications
1.
2020/08/25
Immunotherapy for Lynch Syndrome Patients, Lynch Syndrome: Molecular Mechanism and Current Clinical Practice
■
Journal Articles
1.
2023/01/27
Neutrophil-to-lymphocyte Ratio Prior to Each Chemotherapy Line Predicts Clinical Outcomes in Patients With Unresectable Gastric Cancer
2.
2022/10/14
Genomically Stable Gastric Cancer Characterized by Hypomethylation in Wnt Signal Cascade
3.
2022/06/20
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA
4.
2022/06
A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study
5.
2022/05
Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study
6.
2021/11/27
Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases
7.
2021/11
Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer
8.
2021/05
Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations
9.
2021/02
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)
10.
2020/11/05
The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer
11.
2020/08/24
Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study
12.
2020/07/29
Metronidazole-Induced Encephalopathy during the Treatment of Advanced Esophageal Squamous Cell
Carcinoma
13.
2020/07/21
Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary
14.
2020/07
Molecular Characterization of Second Primary Endometrial Cancer
15.
2020/04/19
Natural history of epithelioid hemangioendothelioma that progressed over 20 years.
16.
2020/04/18
Prognostic nutritional index as a predictor of postoperative outcome in patients aged 85 years or older after colorectal cancer surgery
17.
2020/02/03
Upregulation of microRNA‐31 is associated with poor prognosis in patients with advanced colorectal cancer
18.
2019/10/11
The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)
19.
2019/06
Laparoscopic Rectosigmoid Colon Vaginoplasty in Male-to-Female Transsexuals: Experience in Japan
20.
2019/05
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
21.
2019/03
Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer
22.
2019/02
A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study
23.
2018/10
Detection of Circulating MicroRNAs with Ago2 Complexes to Monitor the Tumor Dynamics of Colorectal Cancer Patients during Chemotherapy
24.
2018/08
Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency
25.
2018/07
Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical bene t in response to prior cetuximab: A retrospective study
26.
2018/06
AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer
27.
2018/04
Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer
28.
2018/04
Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability
29.
2018/04
Risk Analysis for Invasive Fungal Infection after Living Donor Liver Transplantation: Which Patient Needs Potent Prophylaxis?
30.
2018/03
Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles.
31.
2018/02
BRAF V600E mutation is a predictive indicator of upfront chemotherapy for stage IV colorectal cancer
32.
2018/01
Accuracy of four mononucleotide-repeat markers for the identi cation of DNA mismatch-repair de ciency in solid tumors
33.
2018/01
Novel evidence for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in colorectal cancer
34.
2017/10
Living Donor Liver Transplantation for Acute Liver Failure : Comparing Guidelines on the Prediction of Liver Transplantation
35.
2017/08
SNORA21-An Oncogenic Small Nucleolar RNA, with a Prognostic Biomarker Potential in Human Colorectal Cancer
Display 5 items
Display all(35)
■
Presentations
1.
2023/03/15
Pre-treatment PD-1 lymphocyte ratio in blood may predict clinical outcome of gastric cancer patients under Nivolumab monotherapy （Speech，General）
2.
2023/01/19
Impact of RAS and BRAF heterogeneity on the efficacy of EGFR blockade in patients with metastatic colorectal cancer.
3.
2022/10/15
Positioning of cancer genomic medicine in colorectal cancer treatment
Detection of Aberrant DNA Methylation in Circulating Cell Free DNA to Predict Patients with Col-
orectal Cancer （Speech，Panelist at Symposium/Workshop (Applied)）
4.
2022/02/17
A Phase III trial of sequential versus combination in metastatic colorectal cancer: C-Cubed study （Speech，General）
5.
2022/02/17
Fluctuating PD-1 ratio in blood may predict clinical outcome of upper gastrointestinal cancer patients under ICI therapy （Poster notice，General）
6.
2022/01/21
A randomized phase 3 study of sequential versus combination treatment in first-line chemotherapy for metastatic colorectal cancer: The C-cubed study （Poster notice，General）
7.
2021/11/12
Validation and development of the diagnostic technology for Lynch syndrome exclusion by a DNA
chip detecting MLH1 methylation and BRAF V600E mutations in colorectal cancer （Speech，Panelist at Symposium/Workshop (Applied)）
8.
2021/10/02
遺伝性がん 日本におけるリンチ症候群の遺伝学的・臨床的特徴 （Speech，Panelist at Symposium/Workshop (Applied)）
9.
2019/09/29
Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study （Poster notice，General）
10.
2019/07/05
Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors （Poster notice，General）
11.
2019/07/04
Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol （Poster notice，General）
12.
2019/06/03
Validation of biomarkers of preoperative chemoradiotherapy for advanced low rectal cancer and extraction of the high-risk group of recurrence （Poster notice，General）
13.
2019/04/01
Comparing effects of small molecular weight compounds on proliferation and chemotaxis of pancreatic cancer cells （Poster notice，General）
14.
2019/03/21
Precision Medicine to Advanced Colorectal Cancer Patients: A Retrospective Analysis of the Molecular Tumor Board in Okayama University Hospital （Poster notice，General）
15.
2019/01/19
Analysis of UGT1A's polymorphisms and RAS: RAF mutations based on phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer. （Poster notice，General）
16.
2018/11/24
Efficacy of Ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer. （Poster notice，General）
17.
2018/11/24
Incidence of catheter-related thrombosis in patients with long-term indwelling central venous catheter who received chemotherapies for unresectable advanced digestive cancers （Poster notice，General）
18.
2018/11/24
Liquid Biopsy has a potential to predict the colorectal cancer patients with destiny for recurrence after curative surgery （Poster notice，General）
19.
2018/11/10
Clinico-pathological features of hypermutant colorectal cancers analyzed over 1000 colorectal cancer （Speech，Panelist at Symposium/Workshop (Other)）
20.
2018/10/22
Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors （Poster notice，General）
21.
2018/10/21
Distinct Clinico-pathological Features of Hypermutant Colorectal Cancers with POLE Pathogenic Mutations, Lynch Syndrome and Sporadic MSI Analyzed over 1,000 Colorectal Cancer Patients （Poster notice，General）
Display 5 items
Display all(21)
